Towards investigation, development and introduction of cefiderocol in children: product brief
World Health Organization
2023年11月 · World Health Organization
電子書
8
頁
family_home
符合資格
info
report評分和評論未經驗證 瞭解詳情
關於本電子書
In November-December 2022, WHO undertook a Paediatric Drug Optimization (PADO) exercise for antibiotics, to: identify antibiotics with an approved indication for children for which age-appropriate formulations are missing that need to be given priority for development (PADO priority list); and pipeline or approved antibiotics without an indication for children to be given priority for further investigation and development for children (PADO watch list). Cefiderocol was included in the PADO priority list considering its efficacy against multiple pathogens in the WHO Bacterial Priority Pathogens List, its favorable resistance and cross-resistance profile and considering that clinical trials involving children are ongoing.
This information note aims to provide a summary of cefiderocol’s characteristics (regulatory approvals, current formulations, inclusion in the WHO EML etc), current and planned paediatric studies (including neonates) and initiatives to ensure prompt access for all people in need, as well as lay out interventions that should be prioritized by researchers and funders for cefiderocol development, as well as, more broadly for antibiotics that are much needed in children.
This information note aims to provide a summary of cefiderocol’s characteristics (regulatory approvals, current formulations, inclusion in the WHO EML etc), current and planned paediatric studies (including neonates) and initiatives to ensure prompt access for all people in need, as well as lay out interventions that should be prioritized by researchers and funders for cefiderocol development, as well as, more broadly for antibiotics that are much needed in children.
為這本電子書評分
歡迎提供意見。
閱讀資訊
智慧型手機與平板電腦
筆記型電腦和電腦
你可以使用電腦的網路瀏覽器聆聽你在 Google Play 購買的有聲書。
電子書閱讀器與其他裝置
如要在 Kobo 電子閱讀器這類電子書裝置上閱覽書籍，必須將檔案下載並傳輸到該裝置上。請按照說明中心的詳細操作說明，將檔案傳輸到支援的電子閱讀器上。
